A Study to Test if TEV-48574 is Effective in Relieving Asthma

    Not Recruiting
  • days left to enroll
  • participants needed
  • sponsor
    Teva Branded Pharmaceutical Products R&D, Inc.
Updated on 28 April 2022


The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).

The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.

The duration of patient participation in the study is planned to be up to approximately 30 weeks.

Condition Asthma
Treatment Placebo, TEV-48574
Clinical Study IdentifierNCT04545385
SponsorTeva Branded Pharmaceutical Products R&D, Inc.
Last Modified on28 April 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note